Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.


Subscribe or Register

Existing user? Login

Life sciences

‘Hard Brexit’ could delay access to new drugs, think tank warns

A ‘hard Brexit’ could threaten the success of the UK life sciences industry and restrict access to new medicines, a think tank has warned.

If the UK severs ties with the single market and drops out of the current system of regulation by the European Medicines Agency, British patients could end up waiting years longer than those in the United States or EU for the latest treatments, a report from Public Policy Projects concludes.

Luke Tryl, who wrote the report, says: “Simple commercial reality dictates that if companies have to choose between launching drugs in the UK, which accounts for 2.5% of the global market, and the EU, which accounts for 16.6%, then they will prioritise a European launch.

“This effect is compounded if restricted UK health spending means slower take-up in the UK. Ultimately that means British patients losing out on access to new drugs.”

The report also raises concerns about Brexit’s impact on the UK life sciences industry and its position as a global leader.

To safeguard the £60bn contribution the life sciences industry makes to the UK economy, it will be vital to secure single market access for life sciences, guarantee free movement of workers in the industry and ensure maximum regulatory alignment with the EU, the report recommends.

In an introduction to the report, Stephen Dorrell, former Conservative health minister, says: “Science and science-based industry is a global activity and we face a simple choice: we either participate in full in that global scientific community or we prejudice a key British national interest.”

The UK pharmaceutical industry is seeking assurances from ministers about the future.

A life sciences steering group, co-chaired by Andrew Witty, chief executive of GlaxoSmithKline, and Pascal Soriot, chief executive of AstraZeneca, will meet ministers on 23 November 2016 to discuss concerns over regulation, the loss of EU funding and attracting investment.

Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2016.20201902

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

RPS publications

Pharmaceutical Press is the publishing division of the Royal Pharmaceutical Society, and is a leading provider of authoritative pharmaceutical information used throughout the world.


Search an extensive range of the world’s most trusted resources

Powered by MedicinesComplete
  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Supplementary images

  • European Commission headquarters with EU flags

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.